Dallas, TX -- (SBWIRE) -- 06/23/2015 -- The report "Progressive Supranuclear Palsy - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.

Complete report on Progressive Supranuclear Palsy with 19 market data tables and 14 figures, spread across 52 pages is available at http://www.rnrmarketresearch.com/progressive-supranuclear-palsy-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Progressive Supranuclear Palsy - Pipeline Review, H1 2015 report include AlzProtect SAS, Bristol-Myers Squibb Company, Prana Biotechnology Limited, ProteoTech, Inc., Sellas Inc., TauRx Therapeutics Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AZP-2006, BMS-986168, DC-TAB, DP-C016, PBT-434, PTI-51CH3, PTI-51CH3 Backup, TPI-287, TRx-0237, zolpidem tartrate.

Order a purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=392682
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes:

-Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases

-Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

List of Tables
Number of Products under Development for Progressive Supranuclear Palsy, H1 2015 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2015 13
Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H1 2015 14
Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Limited, H1 2015 15
Progressive Supranuclear Palsy - Pipeline by ProteoTech, Inc., H1 2015 16
Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2015 17
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Progressive Supranuclear Palsy Therapeutics - Recent Pipeline Updates, H1 2015 41
Progressive Supranuclear Palsy - Dormant Projects, H1 2015 47

List of Figures
Number of Products under Development for Progressive Supranuclear Palsy, H1 2015 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Explore more reports on Neurology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.